What does 'MHRA-licensed' actually mean?

An MHRA marketing authorisation means the regulator has reviewed the manufacturer's evidence package (clinical trials, safety data, manufacturing controls, labelling) and granted permission to market the medicine in the UK for specific indications, at specific doses, supplied through licensed channels. Three GLP-1-class molecules are MHRA-licensed: tirzepatide (Mounjaro), semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide (Saxenda/Victoza).

Is it legal to buy GLP-1 peptides from research-chemical suppliers?

Research-chemical suppliers in the UK may legally sell research peptides for laboratory and analytical use only. Onward administration of those compounds to a human — including self-administration — is not legal: the material is not a licensed medicine and prescription supply outside the licensed channel is a regulatory offence. Possession itself for genuine research purposes is generally permitted; possession for human use is not.

What is compounded semaglutide?

Compounding is the bespoke preparation of a medicine for an individual patient by a registered pharmacy under a prescriber's authorisation. It is permitted in the UK in narrow circumstances (e.g. when a licensed product is unavailable). Bulk compounding for general supply is not permitted. During the 2022-2024 supply constraints some private clinics used compounded routes; this remains regulatory grey area and the MHRA has issued cautions.

How do I report side effects?

The Yellow Card Scheme is the MHRA's pharmacovigilance reporting channel for both patients and prescribers. Reports can be filed via yellowcard.mhra.gov.uk for any suspected adverse drug reaction. The MHRA collates and analyses these signals; for GLP-1 medicines the cumulative Yellow Card record has informed the Drug Safety Updates issued during 2024-2025.

Is NHS access expanding?

NHS access remains constrained by specialist weight-management service capacity and NICE-recommended eligibility thresholds. The SELECT cardiovascular outcomes data has prompted a NICE consultation on broader semaglutide eligibility — outcome expected mid-2026. Private prescribing pathways remain the dominant access route for adults outside the narrow NHS criteria.

UK MHRA Regulation of GLP-1 & Metabolic Peptides — 2026 Guide

The three regulatory categories

Every metabolic peptide that appears anywhere in the UK supply chain sits in one of three categories. The legal, clinical and patient-safety implications of each differ sharply — the UK regulatory status hub covers all three in depth, alongside advertising rules, online pharmacy verification and grey-market risk.

MHRA-licensed prescription medicines. Tirzepatide (Mounjaro), semaglutide (Ozempic / Wegovy / Rybelsus), liraglutide (Saxenda / Victoza). Manufactured by Eli Lilly or Novo Nordisk under GMP. Supplied through licensed UK pharmacies on the authority of a registered prescriber. Indications and doses are defined in the Summary of Product Characteristics and the BNF.
Compounded licensed medicines. Pharmacy-prepared versions of an MHRA-licensed molecule for an individual patient, typically when a licensed product is unavailable. Compounded products are not the same regulated medicine — sterility, stability and purity are the compounding pharmacy's responsibility. The MHRA monitors compounded supply and has issued cautions during periods of high demand.
Research peptides (unlicensed). Retatrutide, AOD-9604, HGH Fragment 176-191, tesamorelin, CJC-1295, ipamorelin. Supplied for laboratory and analytical use only by research-chemical suppliers. Not licensed for human therapeutic use. Onward supply to a patient is a regulatory offence.

What the MHRA actually does

The Medicines and Healthcare products Regulatory Agency is the UK national regulator. It (1) grants marketing authorisations for medicines, (2) inspects manufacturing sites and licensed pharmacies, (3) maintains the Yellow Card Scheme for adverse-event reporting, and (4) issues Drug Safety Updates when new evidence warrants changes to prescribing practice. Since EU exit, the MHRA has issued a number of its own authorisations independent of EMA — but for the GLP-1 class, MHRA and EMA decisions have largely tracked together.

How a new GLP-1 reaches UK patients

The standard pathway runs: pivotal Phase 3 trial completes → manufacturer files marketing-authorisation application → MHRA assessment (typically 6-12 months) → SmPC and label published → product launched into the supply chain → NICE assesses cost-effectiveness for NHS use → NHS access pathway opens (or doesn't) → private supply runs in parallel. For retatrutide this pathway is currently in the trial-completion phase; for tirzepatide the weight-management indication completed it in 2024.

NHS vs private prescribing

NHS access to Wegovy and Mounjaro for weight management is restricted to adults meeting NICE-defined eligibility (broadly BMI ≥35 with comorbidity, via specialist weight-management service referral; the 2024 NICE guidance extended some eligibility). Private prescribers — GP-led services, weight-management clinics, online providers — operate under standard UK-private prescribing rules and account for the majority of UK supply. Pharmacist-led services are now licensed for limited indications.

The Yellow Card Scheme

The Yellow Card Scheme (yellowcard.mhra.gov.uk) is the UK's pharmacovigilance reporting channel. Both prescribers and patients can file reports. For the GLP-1 class, the cumulative Yellow Card data has informed MHRA Drug Safety Updates on gastrointestinal tolerability (2024), pancreatitis vigilance (ongoing class warning), and gallbladder events with rapid weight loss. Use of the Scheme by patients is encouraged where any unexpected adverse event occurs.

Enforcement against unlicensed supply

The MHRA periodically takes enforcement action against unlicensed online supply of GLP-1 medicines and related compounds. Recent activity has focused on websites selling unlicensed semaglutide or tirzepatide directly to UK consumers, sometimes using the brand names of licensed medicines without authorisation. Such products are typically of unknown manufacture and origin; consumers should source MHRA-licensed medicines only through the regulated pharmacy supply chain.

FAQs

What does 'MHRA-licensed' actually mean?: An MHRA marketing authorisation means the regulator has reviewed the manufacturer's evidence package (clinical trials, safety data, manufacturing controls, labelling) and granted permission to market the medicine in the UK for specific indications, at specific doses, supplied through licensed channels. Three GLP-1-class molecules are MHRA-licensed: tirzepatide (Mounjaro), semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide (Saxenda/Victoza).
Is it legal to buy GLP-1 peptides from research-chemical suppliers?: Research-chemical suppliers in the UK may legally sell research peptides for laboratory and analytical use only. Onward administration of those compounds to a human — including self-administration — is not legal: the material is not a licensed medicine and prescription supply outside the licensed channel is a regulatory offence. Possession itself for genuine research purposes is generally permitted; possession for human use is not.
What is compounded semaglutide?: Compounding is the bespoke preparation of a medicine for an individual patient by a registered pharmacy under a prescriber's authorisation. It is permitted in the UK in narrow circumstances (e.g. when a licensed product is unavailable). Bulk compounding for general supply is not permitted. During the 2022-2024 supply constraints some private clinics used compounded routes; this remains regulatory grey area and the MHRA has issued cautions.
How do I report side effects?: The Yellow Card Scheme is the MHRA's pharmacovigilance reporting channel for both patients and prescribers. Reports can be filed via yellowcard.mhra.gov.uk for any suspected adverse drug reaction. The MHRA collates and analyses these signals; for GLP-1 medicines the cumulative Yellow Card record has informed the Drug Safety Updates issued during 2024-2025.
Is NHS access expanding?: NHS access remains constrained by specialist weight-management service capacity and NICE-recommended eligibility thresholds. The SELECT cardiovascular outcomes data has prompted a NICE consultation on broader semaglutide eligibility — outcome expected mid-2026. Private prescribing pathways remain the dominant access route for adults outside the narrow NHS criteria.